Skip to content

In the BioHarmony Drug Report Database

Aripiprazole

Abilify (aripiprazole) is a small molecule pharmaceutical. Aripiprazole was first approved as Abilify on 2002-11-15. It is used to treat schizophrenia and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat bipolar disorder and schizophrenia. The pharmaceutical is active against D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 1D, histamine H1 receptor, 5-hydroxytryptamine receptor 1A, D(4) dopamine receptor, 5-hydroxytryptamine receptor 7, 5-hydroxytryptamine receptor 6, and albumin. Aripiprazole's patents are valid until 2034-03-08 (FDA).
Trade Name Abilify, Abilify Maintena
Common Name Aripiprazole
Indication bipolar disorder, schizophrenia, schizophrenia spectrum and other psychotic disorders
Drug Class Antiulcer agents (benzimidazole derivatives)
Aripiprazole
Get full access now